Novo Nordisk has adjusted its projections for 2025, citing lower-than-anticipated demand for its leading weight loss and diabetes medications. This revision comes as a result of the growing availability of compounded semaglutide products, which have begun to affect sales of its flagship drugs, Wegovy and Ozempic. Despite these challenges, the company reported a robust performance in the first quarter of 2025, with total revenues increasing by 18% and operating profit by 20%.
The diabetes and obesity care segment remains a significant revenue source for Novo Nordisk, but the stagnation of Wegovy prescriptions since February raises concerns about its competitive position, particularly against Eli Lilly's offerings. Analysts have expressed mixed views on the company’s future, with some projecting a potential increase in demand later in the year, while others remain cautious.
In response to the competitive landscape and the rise of compounding pharmacies, Novo Nordisk is taking proactive measures. The company has partnered with telehealth providers to enhance access to its legitimate products and combat the risks associated with unregulated compounding.
As the market dynamics evolve, Novo Nordisk’s strategy will be crucial in maintaining its foothold in the obesity and diabetes treatment sectors. The company's ability to navigate these challenges will determine its growth trajectory and market share in the coming years.
